Literature DB >> 16687097

Evolving concepts in the management of lobular neoplasia.

Benjamin O Anderson1, Kristine E Calhoun, Eric L Rosen.   

Abstract

Lobular neoplasia broadly defines the spectrum of changes within the lobule, ranging from atypical lobular hyperplasia (ALH) to lobular carcinoma in situ (LCIS). This continuum of lesions is associated with an increased risk for developing subsequent invasive breast cancer, with the magnitude of that risk corresponding to the degree of proliferative change. The associated risk for developing invasive breast cancer after a diagnosis of lobular neoplasia is multicentric, bilateral, and equal in both breasts. Lobular neoplasia itself may transform into invasive carcinoma, although the frequency of this occurrence is unknown. Thus, lobular neoplasia is a risk factor for invasive breast cancer and may be a precursor lesion in unusual circumstances. The management of ALH and LCIS depends on the setting in which they are encountered. When ALH and LCIS are diagnosed after core needle breast biopsy, wire localization for surgical excision is required for definitive diagnosis because rates of histologic underestimation approach those of atypical ductal hyperplasia (ADH). When diagnosed on surgical biopsy, ALH and LCIS generally do not require further intervention, even when present at a surgical margin. However, bilateral breast cancer risk must be considered, especially when patients have a family history of breast cancer. In selected situations, bilateral prophylactic mastectomy with or without reconstruction may be considered when atypical hyperplasia or LCIS is diagnosed. Although this reduces risk for developing subsequent breast carcinoma by 90%, patients selected for prophylactic mastectomy represent a small subgroup of lobular neoplasia patients and generally have other risk factors, such as strong family history or evidence of genetic predisposition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16687097     DOI: 10.6004/jnccn.2006.0041

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  9 in total

1.  MR-guided stereotactic breast biopsy using a mixed ferromagnetic-nonmagnetic coaxial system with 12- to 18-gauge needles: clinical experience and long-term outcome.

Authors:  Elena Belloni; Pietro Panizza; Silvia Ravelli; Francesco De Cobelli; Simone Gusmini; Claudio Losio; Isabella Sassi; Gianluca Perseghin; Alessandro Del Maschio
Journal:  Radiol Med       Date:  2013-06-25       Impact factor: 3.469

2.  Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study.

Authors:  Maeve Mullooly; Zeina G Khodr; Cher M Dallal; Sarah J Nyante; Mark E Sherman; Roni Falk; Linda M Liao; Jeffrey Love; Louise A Brinton; Gretchen L Gierach
Journal:  Am J Epidemiol       Date:  2017-12-15       Impact factor: 4.897

3.  Biologic characteristics of premalignant breast disease.

Authors:  Kimberly Cole; Maria Tabernero; Karen S Anderson
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

4.  Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study.

Authors:  Lynn C Hartmann; Derek C Radisky; Marlene H Frost; Richard J Santen; Robert A Vierkant; Lorelle L Benetti; Yaman Tarabishy; Karthik Ghosh; Daniel W Visscher; Amy C Degnim
Journal:  Cancer Prev Res (Phila)       Date:  2014-01-30

5.  Lobular neoplasia detected in MRI-guided core biopsy carries a high risk for upgrade: a study of 63 cases from four different institutions.

Authors:  Thaer Khoury; Prasanna R Kumar; Zaibo Li; Rouzan G Karabakhtsian; Souzan Sanati; Xiwei Chen; Dan Wang; Song Liu; Beatriu Reig
Journal:  Mod Pathol       Date:  2015-11-13       Impact factor: 7.842

6.  Serological thymidine kinase 1 is a biomarker for early detection of tumours--a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay.

Authors:  Zhi Heng Chen; Shou Qing Huang; Yande Wang; Ai Zhen Yang; Jian Wen; Xiao Hong Xu; Yan Chen; Qu Bo Chen; Ying Hong Wang; Ellen He; Ji Zhou; Sven Skog
Journal:  Sensors (Basel)       Date:  2011-11-28       Impact factor: 3.576

7.  Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases.

Authors:  Bruno Cutuli; Brigitte De Lafontan; Youlia Kirova; Hugues Auvray; Agnes Tallet; Sandrine Avigdor; Claire Brunaud; Catherine Delva
Journal:  Radiat Oncol       Date:  2015-05-06       Impact factor: 3.481

8.  Mapping breast tissue types by miniature radio-frequency near-field spectroscopy sensor in ex-vivo freshly excised specimens.

Authors:  Zvi Kaufman; Haim Paran; Ilana Haas; Patricia Malinger; Tania Zehavi; Tamar Karni; Izhak Pappo; Judith Sandbank; Judith Diment; Tanir Allweis
Journal:  BMC Med Imaging       Date:  2016-10-10       Impact factor: 1.930

9.  Clonal relationships between lobular carcinoma in situ and other breast malignancies.

Authors:  Colin B Begg; Irina Ostrovnaya; Jose V Scarpa Carniello; Rita A Sakr; Dilip Giri; Russell Towers; Michail Schizas; Marina De Brot; Victor P Andrade; Audrey Mauguen; Venkatraman E Seshan; Tari A King
Journal:  Breast Cancer Res       Date:  2016-06-23       Impact factor: 6.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.